Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

被引：9

作者：

Schmidt, Walker M. ^{[1
]}

Perera, Nirosha D. ^{[2
]}

Buadi, Francis K. ^{[3
]}

Hayman, Suzanne R. ^{[3
]}

Kumar, Shaji K. ^{[3
]}

Dispenzieri, Angela ^{[3
]}

Dingli, David ^{[3
]}

Cook, Joselle ^{[3
]}

Lacy, Martha Q. ^{[3
]}

Kapoor, Prashant ^{[3
]}

Leung, Nelson ^{[4
]}

Muchtar, Eli ^{[3
]}

Warsame, Rahma M. ^{[3
]}

Kourelis, Taxiarchis ^{[3
]}

Binder, Moritz ^{[3
]}

Gonsalves, Wilson I. ^{[3
]}

Hogan, William J. ^{[3
]}

Gertz, Morie A. ^{[3
]}

机构：

[1] Mayo Clin, Alix Sch Med, Rochester, MN 55902 USA

[2] Mayo Clin, Dept Internal Med, Rochester, MN USA

[3] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[4] Mayo Clin, Dept Internal Med, Div Nephrol, Rochester, MN USA

来源：

BLOOD CANCER JOURNAL | 2023年 / 13卷 / 01期

关键词：

AUTOLOGOUS TRANSPLANTATION; CONSENSUS CONFERENCE; CLINICAL-TRIALS; CRITERIA; TRENDS; BLOOD;

D O I：

10.1038/s41408-023-00900-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative in some, while toxic in many others. We retrospectively analyzed 85 patients diagnosed with MM who underwent allo SCT as frontline or salvage therapy between 2000 and 2022 at Mayo Clinic Rochester and examined patient outcomes and prognostic markers. Overall survival (OS), progression free survival (PFS), treatment related mortality (TRM), and relapse rates (RR) were estimated using the Kaplan Meier method and competing risk models. Median follow-up was 11.5 years. Median OS and PFS were 1.7 and 0.71 years, respectively. Five-year OS and PFS were 22.2% and 15.1%, respectively. One-year TRM was 23.5%. Twelve patients demonstrated durable overall survival, living 10+ years beyond their allo SCT. This subgroup was more likely to have no or one prior auto SCT (p = 0.03) and to have been transplanted between 2000 and 2010 (p = 0.03). Outcomes were poor in this cohort with long follow-up, with few patients surviving 5 years or more, and most relapsing or dying within 2 years. We would expect better outcomes and tolerability with an expanded array of novel therapeutics and would prefer them to allo SCT.

引用

页数：8

共 29 条

[1]

AALEN OO, 1978, SCAND J STAT, V5, P141

[2] Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation [J].

Auner, H. W. ;

Szydlo, R. ;

van Biezen, A. ;

Iacobelli, S. ;

Gahrton, G. ;

Milpied, N. ;

Volin, L. ;

Janssen, J. ;

Quoc, S. Nguyen ;

Michallet, M. ;

Schoemans, H. ;

el Cheikh, J. ;

Petersen, E. ;

Guilhot, F. ;

Schoenland, S. ;

Ahlberg, L. ;

Morris, C. ;

Garderet, L. ;

de Witte, T. ;

Kroeger, N. .

BONE MARROW TRANSPLANTATION, 2013, 48 (11) :1395-1400

[3] Defining the Intensity of Conditioning Regimens: Working Definitions [J].

Bacigalupo, Andrea ;

Ballen, Karen ;

Rizzo, Doug ;

Giralt, Sergio ;

Lazarus, Hillard ;

Ho, Vincent ;

Apperley, Jane ;

Slavin, Shimon ;

Pasquini, Marcelo ;

Sandmaier, Brenda M. ;

Barrett, John ;

Blaise, Didier ;

Lowski, Robert ;

Horowitz, Mary .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) :1628-1633

[4] Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning [J].

Crawley, Charles ;

Iacobelli, Simona ;

Bjorkstrand, Bo ;

Apperley, Jane F. ;

Niederwieser, Dietger ;

Gahrton, Gosta .

BLOOD, 2007, 109 (08) :3588-3594

[5] Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma [J].

de Lavallade, H. ;

El-Cheikh, J. ;

Faucher, C. ;

Fuerst, S. ;

Stoppa, A-M ;

Coso, D. ;

Bouabdallah, R. ;

Chabannon, C. ;

Gastaut, J-A ;

Blaise, D. ;

Mohty, M. .

BONE MARROW TRANSPLANTATION, 2008, 41 (11) :953-960

[6] Allogeneic stem cell transplantation for multiple myeloma: is there a future? [J].

Dhakal, B. ;

Vesole, D. H. ;

Hari, P. N. .

BONE MARROW TRANSPLANTATION, 2016, 51 (04) :492-500

[7] Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma [J].

Efebera, Yvonne A. ;

Qureshi, Sofia R. ;

Cole, Suzanne M. ;

Saliba, Rima ;

Pelosini, Matteo ;

Patel, Ronak M. ;

Koca, Ebru ;

Mendoza, Floralyn L. ;

Wang, Michael ;

Shah, Jatin ;

Alousi, Amin ;

Hosing, Chitra ;

Popat, Uday ;

Kebriaei, Partow ;

Anderlini, Paolo ;

Khouri, Issa F. ;

Champlin, Richard ;

Giralt, Sergio ;

Qazilbash, Muzaffar H. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) :1122-1129

[8] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[9] Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study [J].

Gahrton, Gosta ;

Iacobelli, Simona ;

Bjorkstrand, Bo ;

Hegenbart, Ute ;

Gruber, Astrid ;

Greinix, Hildegard ;

Volin, Liisa ;

Narni, Franco ;

Carella, Angelo Michele ;

Beksac, Meral ;

Bosi, Alberto ;

Milone, Giuseppe ;

Corradini, Paolo ;

Schoenland, Stefan ;

Friberg, Kristina ;

van Biezen, Anja ;

Goldschmidt, Hartmut ;

de Witte, Theo ;

Morris, Curly ;

Niederwieser, Dietger ;

Garderet, Laurent ;

Kroeger, Nicolaus .

BLOOD, 2013, 121 (25) :5055-5063

[10] Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma [J].

Giaccone, Luisa ;

Storer, Barry ;

Patriarca, Francesca ;

Rotta, Marcello ;

Sorasio, Roberto ;

Allione, Bernardino ;

Carnevale-Schianca, Fabrizio ;

Festuccia, Moreno ;

Brunello, Lucia ;

Omede, Paola ;

Bringhen, Sara ;

Aglietta, Massimo ;

Levis, Alessandro ;

Mordini, Nicola ;

Gallamini, Andrea ;

Fanin, Renato ;

Massaia, Massimo ;

Palumbo, Antonio ;

Ciccone, Giovannino ;

Storb, Rainer ;

Gooley, Ted A. ;

Boccadoro, Mario ;

Bruno, Benedetto .

BLOOD, 2011, 117 (24) :6721-6727

← 1 2 3 →